Clinical Trial Detail

NCT ID NCT02545283
Title A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

acute myeloid leukemia

Therapies

Cytarabine

Cytarabine + Idasanutlin

Age Groups: adult

No variant requirements are available.